MedTrace Logo

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on inflammation and a secondary emphasis on clinical efficacy

Conditions

Interventions

DRUG

budesonide/formoterol, 2x 200/6 microgram. 4 times daily

DRUG

prednisolone, 30 mg once daily and placebo

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Netherlands Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2005-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239278 on ClinicalTrials.gov